Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.

The conversation is about seeking advice on the potential benefits of two different hair sprays for hair loss, with a list of ingredients provided for each. Specific treatments were not discussed.

A user speculates that a fast metabolism might affect the effectiveness of dutasteride for hair loss. Another user argues that drug response is unrelated to metabolism speed.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

The user experiences side effects from minoxidil and is considering alternatives like stemoxydine and adenosine for hair regrowth and density, but finds options like caffeine and various oils unreliable. They are also using a 5AR inhibitor (finasteride).

Focus on scalp health, not just DHT suppression, is crucial for hair regrowth. Effective treatments include Hair Restoration shampoo, LLLT laser cap, microneedling, and topical finasteride.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The user is already using topical finasteride and minoxidil for hair loss and is considering adding topical caffeine. They are seeking opinions on the effectiveness of topical caffeine.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.

The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and other methods like PRP, laser, and mesotherapy. Despite these treatments, the user is experiencing hair loss, and others suggest consulting a dermatologist, considering alternative treatments, and addressing potential scalp inflammation.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The user is frustrated with ongoing hair loss despite using treatments like finasteride, dutasteride, minoxidil, RU58841, and others. They express concern over the lack of improvement in hair density and the emotional toll it takes.

Hair loss impacts mental health and should be covered by healthcare, with treatments like finasteride, dutasteride, and minoxidil being affordable and effective. Some argue hair loss is cosmetic and shouldn't be funded, while others highlight its broader health implications.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

Mixing charcoal, Ketoconazole, and caffeinated shampoo is questioned for potential interaction, specifically if charcoal inactivates other ingredients. Charcoal is used for seborrheic dermatitis, while caffeine is thought to improve scalp blood flow.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation discusses hair loss treatments, focusing on the use of finasteride (fin) and minoxidil (min), with some users recommending dutasteride (dut) for stronger results. Many users emphasize that these treatments are affordable and effective, with some sharing personal experiences of hair regrowth and side effects.

Shampoos, including those with aminexil, are generally ineffective for hair loss and are considered overpriced. Minoxidil and finasteride are more effective treatments.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

Finasteride is being discussed as a significant treatment for male baldness, with some users sharing positive experiences and increased confidence, while others express concerns about potential side effects like loss of libido and erectile dysfunction. The conversation highlights differing opinions on the drug's impact and the broader societal implications of changing beauty standards.